Deutsche Bank AG Purchases 34,739 Shares of Asterias Biotherapeutics (AST)

Deutsche Bank AG raised its position in Asterias Biotherapeutics (NYSEAMERICAN:AST) by 110.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 66,180 shares of the biotechnology company’s stock after buying an additional 34,739 shares during the period. Deutsche Bank AG’s holdings in Asterias Biotherapeutics were worth $148,000 as of its most recent filing with the SEC.

Separately, Virtu Financial LLC boosted its position in Asterias Biotherapeutics by 387.0% in the 4th quarter. Virtu Financial LLC now owns 71,588 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 56,888 shares during the last quarter.

Shares of Asterias Biotherapeutics opened at $1.65 on Thursday, according to Marketbeat. Asterias Biotherapeutics has a 52 week low of $1.20 and a 52 week high of $3.75.



Asterias Biotherapeutics (NYSEAMERICAN:AST) last announced its quarterly earnings data on Wednesday, May 9th. The biotechnology company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.03. The firm had revenue of $0.48 million for the quarter. Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%.

A number of brokerages have commented on AST. B. Riley set a $6.00 price objective on Asterias Biotherapeutics and gave the company a “buy” rating in a research report on Thursday, March 1st. Zacks Investment Research lowered Asterias Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 20th. Finally, HC Wainwright set a $11.00 price objective on Asterias Biotherapeutics and gave the company a “buy” rating in a research report on Friday, March 16th.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.

Want to see what other hedge funds are holding AST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Asterias Biotherapeutics (NYSEAMERICAN:AST).

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply